Inaugural Global Rare Impact Award: Sanofi Honors The 3 Remarkable Pioneers
Ekaterina Kazakova, Medical Executive at Sanofi, reposted from Alaa Hamed on LinkedIn:
”Proud to share this meaningful initiative led by Sanofi recognizing leaders who have dedicated their lives to improving the rare disease landscape.
Projects like this are essential for raising awareness, strengthening patient advocacy, and highlighting the extraordinary efforts driving progress for rare communities worldwide.
We need more initiatives like this across all continents to ensure broader visibility, support, and impact.”
Quoting Alaa Hamed‘s post:
”Last week, at our Inaugural Global Rare Impact Awards ceremony November 14, 2025 in Vienna, we honored three remarkable pioneers:
Tiffany House A visionary leader in global patient advocacy, particularly in the Pompe community, setting the gold standard for collaborative advocacy leadership worldwide.
Maryze Schoneveld van der Linde A beacon of hope for rare disease patients in developing countries, distinguished board member of the International Pompe Association, and tireless advocate for patient needs globally.
Dr. I. C. Verma Known as the “Father of Genetics” in India, Dr. Verma established two groundbreaking genetic centers and pioneered affordable genetic testing.
His compassionate access program has helped treat over 300 patients with lysosomal storage disorders.
We are pleased to recognize these exceptional individuals who have dedicated their lives to transforming the rare disease landscape and those who have demonstrated outstanding leadership and unwavering commitment to the rare disease community for more than two decades.
This award embodies Sanofi’s commitment to recognizing those remarkable individuals who have dedicated their lives to advancing rare disease causes.
Their tireless efforts have created lasting changes in the rare disease community, improving countless lives worldwide.”
More winner stories featured in Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women